Bristol-Myers Squibb is a leading pharmaceutical company with a strong pipeline. However, the stock is been stagnant in 2020 and therefore remains significantly undervalued here at the beginning of 2021. With this video I attempt to illustrate reasons why the market has been neglecting this blue-chip and then elaborate on whether it is justified or not.

— Chuck Carnevale

Investors Can't Afford to Miss This [sponsor]
To carry out Trump's Executive Order #14196 initiative, the administration will have to partner with a handful of U.S. companies that control the "reserve accounts" sitting on trillions of dollars' worth of untapped natural resources. I've spent months digging into this – and I've identified three companies that have already been granted "emergency status" and fast-track approvals. I believe their shares could skyrocket once new capital starts moving into the sector. See the three stocks that I expect to be the biggest winners as this plan rolls.

Source: FAST Graphs